StockData
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. (AMRX) stock analysis

AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 12/3066% above fair value
$21.71+0.33 (+1.54%)

Close on Nov 11, 2026Market cap $6.93BP/E 51.7Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth5Performance5Health2Dividend0

Mixed12 of 30 checks passed

Amneal Pharmaceuticals passes 12 of the 30 checks behind our score; 9 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
5/6
Past performance
5/6
Financial health
2/6
Dividend
0/6

What stands out

  • Return on capital over 10%

    Return on invested capital was 16.3%, above the 10% that usually covers the cost of capital.

  • Earnings grew over 5 years

    Net income grew 1.2% a year on average over the last five fiscal years.

  • Revenue growing 10%+ a year

    Revenue grew 10.9% a year over the last three fiscal years.

  • Earnings growth accelerating

    Net income grew 2159% over the last twelve months, against a 5-year average of 1.2% a year.

What to watch

  • Margin of safety under 20%

    The price is 66.0% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $21.71 is above our fair value estimate of $13.08.

  • High debt

    Debt is 553% of shareholders' equity, above the 40% we consider low.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals 6.1% of total debt; we look for at least 20%.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E above the industry

    Amneal Pharmaceuticals's P/E of 51.7 is above the Drugs median of 25.1.

  • EV/EBITDA above its 5-year median

    Amneal Pharmaceuticals's EV/EBITDA of 20.3 is above its 5-year median of 18.5.

  • P/B above the industry

    Amneal Pharmaceuticals's price-to-book of 13.05 is above the Drugs median of 2.29.

  • Trading above fair value

    The share price of $21.71 is above our fair value estimate of $13.08.

  • Margin of safety under 20%

    The price is 66.0% above fair value, so there is no margin of safety.

Growth5/6

  • Revenue growing 10%+ a year

    Revenue grew 10.9% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings growth accelerating

    Net income grew 2159% over the last twelve months, against a 5-year average of 1.2% a year.

  • Growing faster than the industry

    Revenue grew 8.9% over the last twelve months; the Drugs median is 8.0%.

  • Guidance raised

    Amneal Pharmaceuticals raised its full year 2026 Net revenue outlook on Nov 3, 2026.

  • Gross margin improving

    Gross margin was 40.2% over the last twelve months, against 36.8% a year earlier.

Past performance5/6

  • Return on equity

    Needs positive equity and five years of results.

  • Return on capital over 10%

    Return on invested capital was 16.3%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Amneal Pharmaceuticals's return on equity of 63.2% is above the Drugs median of -58.9%.

  • Earnings grew over 5 years

    Net income grew 1.2% a year on average over the last five fiscal years.

  • Net margin above its 5-year average

    Net margin was 4.2% over the last twelve months, against a 5-year average of -3.4%.

  • Net margin above the industry

    Amneal Pharmaceuticals's net margin of 4.2% is above the Drugs median of -53.0%.

Financial health2/6

  • High debt

    Debt is 553% of shareholders' equity, above the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 917% five years ago to 553%.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals 6.1% of total debt; we look for at least 20%.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets cover short-term debts

    Current assets are 1.87 times current liabilities.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 1.89; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Amneal Pharmaceuticals has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$13.08

The share price is 66% above this estimate.

20%+ below
Near fair value
20%+ above
$21.71Price$13.08Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E25.1×–25.1×$10.5444%
EV/EBITDA17.8×18.5×17.1×$18.0139%
Earnings power10.2% cost of equity––$8.3317%
Fair value$13.08100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Drugs median 25.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$83.15M
Value traded per 1% price move
$29.38M

Downside

Medium risk

Typical loss in a bad month
17.5%
Volatility (annualized)
35%
Sharpe ratio, 1 year
2.39
Beta to the S&P 500 (5Y)
1.07

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2015 to 2025

Gross margin

36.9%+5.3 pts over 5 years

Operating margin

13.1%+8.5 pts over 5 years

Net margin

2.4%−1.0 pts over 5 years

See a number that looks wrong?